Evidence map›Paper›PMID 28035071›Full record

ArticleOncotarget2017

Heterogeneity in sarcoma cell lines reveals enhanced motility of tetraploid versus diploid cells.

Mohamed Jemaà, Samer Abdallah, Gwendaline Lledo, Gaelle Perrot, Tom Lesluyes, Catherine Teyssier, Pierre Roux, Juliette van Dijk, Frederic Chibon, Ariane Abrieu and 1 more

Abstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Tetraploidization Increases the Motility and Invasiveness of Cancer Cells.International journal of molecular sciences · 2023
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mohamed JemaàUniversités de Montpellier, 34293 Montpellier, France.
Samer AbdallahUniversités de Montpellier, 34293 Montpellier, France.
Gwendaline LledoUniversités de Montpellier, 34293 Montpellier, France.
Gaelle PerrotINSERM U1218, Bergonié Cancer Institute, F-33076 Bordeaux, France.
Tom LesluyesINSERM U1218, Bergonié Cancer Institute, F-33076 Bordeaux, France.
Catherine TeyssierU1194 INSERM, IRCM, 34298 Montpellier, France.
Pierre RouxUniversités de Montpellier, 34293 Montpellier, France.
Juliette van DijkUniversités de Montpellier, 34293 Montpellier, France.
Frederic ChibonINSERM U1218, Bergonié Cancer Institute, F-33076 Bordeaux, France.
Ariane AbrieuUniversités de Montpellier, 34293 Montpellier, France.
Nathalie MorinUniversités de Montpellier, 34293 Montpellier, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Soft tissue sarcomas with complex genomics are very heterogeneous tumors lacking simple prognosis markers or targeted therapies. Overexpression of a subset of mitotic genes from a signature called CINSARC is of bad prognosis, but the significance of this signature remains elusive. Here we precisely measure the cell cycle and mitosis duration of sarcoma cell lines and we found that the mitotic gene products overexpression does not reflect variation in the time spent during mitosis or G2/M. We also found that the CINSARC cell lines, we studied, are composed of a mixture of aneuploid, diploid, and tetraploid cells that are highly motile in vitro. After sorting diploid and tetraploid cells, we showed that the tetraploid cell clones do not possess a proliferative advantage, but are strikingly more motile and invasive than their diploid counterparts. This is correlated with higher levels of mitotic proteins overexpression. Owing that mitotic proteins are almost systematically degraded at the end of mitosis, we propose that it is the abnormal activity of the mitotic proteins during interphase that boosts the sarcoma cells migratory properties by affecting their cytoskeleton. To test this hypothesis, we designed a screen for mitotic or cytoskeleton protein inhibitors affecting the sarcoma cell migration potential independently of cytotoxic activities. We found that inhibition of several mitotic kinases drastically impairs the CINSARC cell invasive and migratory properties. This finding could provide a handle by which to selectively inhibit the most invasive cells.

Indexed as

Cell LineCell MovementDiploidyDNA, NeoplasmGenetic HeterogeneityHumansSarcomaTetraploidyDNA, NeoplasmCINSARCdiploid/tetraploidmitosismotilitysarcoma

Identifiers

PMID28035071
PMCPMC5369993

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.